OR WAIT null SECS
The 11th Annual Global Biomanufacturing Study includes a global analysis of 238 biomanufacturers and 178 suppliers in 31 countries.
BioPlan Associates has released the 11th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production. This report includes a global analysis of 238 biomanufacturers and 178 suppliers in 31 countries. The 514-page study contains 11 years of biopharma trends and opportunities, including analysis of specific issues affecting the industry. The report covers the events shaping the past year, and evaluates what will shape the industry over the next five years. The study focuses on 12 areas, including industry growth, downstream processing, single use systems, outsourcing, capacity, and quality management.
The data on global capacity reveals how the impact of biosimilars, outsourcing, regulatory, as well as downstream processing and single-use devices, are creating growth potential in both capacity and in the number of facilities coming on-line. Capacity utilization remains overall constant across mammalian and microbial systems, according to this year's respondents. This will affect, overall industry growth, opportunities for suppliers to the industry, demand for skilled staff and better technology, and regulatory demands on the industry.
In addition, the report features analysis on how trends such as mAbs, biosimilars, outsourcing, and disposables are creating opportunities and challenges to the entire industry. The study also compares over time how Western Europe, the US, and other global biomanufacturers differ in demands for new technologies.
Source: BioPlan Associates